Increased scrutiny and new regulation have seen pharma’s relationship with key opinion leaders (KOLs) undergo a paradigm shift in recent years.
Survey on the rising use of Inter Partes Reviews to challenge patents reveals key considerations for originator companies.
Outlining the four core elements pharma companies need to lay the foundation for a solid digital health infrastructure.
As the UK exits the European Union, the pharmaceutical and life sciences industries should prepare for changes by identifying key business issues, mitigating risks and creating plans for multiple scenarios.
The latest price rules revision is both radical and rare by the government’s usual exhaustive standards. What do the new rules mean for pharma players in the world’s third-largest market?
The secret sauce for creating blockbuster brands has always been - and always will be - consistently exceptional team execution. Andy Mehrotra offers the recipe.
Vice President, Psychiatry Marketing, Lundbeck US
Survey on the rising use of Inter Partes Reviews to challenge patents reveals key considerations for originator companies.
A practical roadmap for pharma brand teams in avoiding the pitfalls in statistical thinking when appraising and presenting data.
Michael Gordon charts the evolution of regulatory operations and suggests how it can spearhead opportunities for innovation in pharma data.
To successfully commercialize orphan drugs, companies need to set aside general medicine strategies and adopt a more granular approach to identifying and capitalizing on commercial opportunities.
Digital disruption is poised to usher in a new era of customer-centricity and efficiency, starting with trials and precision targeting.
Milana Chamberlain and George Cameron ask: is it time for pharma to start using human rights language?
Loss of exclusivity (LOE) doesn’t have to be the death knell for branded drug revenue streams. The key approaches to preserving meaningful value well into the post-patent-loss future are outlined.
Loss of exclusivity (LOE) doesn’t have to be the death knell for branded drug revenue streams. The key approaches to preserving meaningful value well into the post-patent-loss future are outlined.
Loss of exclusivity (LOE) doesn’t have to be the death knell for branded drug revenue streams. The key approaches to preserving meaningful value well into the post-patent-loss future are outlined.
Milana Chamberlain and George Cameron ask: is it time for pharma to start using human rights language?
Pharmaceutical Research and Manufacturers of America (PhRMA) International Vice-President Jay Taylor has expressed the organization’s concerns over the Office of the United States Trade Representative’s (USTR) 2013 Special 301 Report.
The Tufts University Center for the Study of Drug Development (CSDD) released its latest research on the costs and timeframes required for launching a new drug.
CPhI report notes that the Indonesian pharma market is on the brink of a regional manufacturing boom, with market capitalizations and company values rising.
Life sciences: the time is now for a comprehensive big data strategy.
In patient support programs, success-and your ROI-rests on making that vital connection between technology and the human touch.
Biosimilars are gaining more support among payers and physicians, but more needs to be done to explain their benefits as well as their safety and efficacy profiles, writes Barbara Testa.